KLK3 and prostate carcinoma: Since prostate cancer (PCa) is the second most common cancer in men with 1.4 million new cases and 400,000 deaths every year, predominantly KLK3/PSA and to a lesser extent KLK2 have become diagnostic tools and drug targets [137,138].